Organised live events sector in India grows 15% in 2024, adds Rs 13 billion in revenue: Report
The whitepaper on India's Live Entertainment Economy, presented by EVENTFAQS MEDIA, added that 2024-25 period marked a critical turning point, highlighted by the successful return of global icons like Coldplay, who performed sold-out concerts in Ahmedabad and Mumbai.
These shows, among Asia's most attended and technologically sophisticated, illustrated India's readiness to host world-class events, reinforcing its position as a pivotal destination on global touring routes.
The document added that the event tourism has surged dramatically, with nearly half a million fans travelling between cities specifically to attend live music events, signalling the rise of a vibrant music-tourism economy.
Premium ticketing categories such as VIP experiences, curated access zones, and luxury hospitality packages saw a year-on-year growth of over 100 per cent, demonstrating a maturing, experience-focused audience willing to spend significantly on premium event experiences, as per the whitepaper.
The whitepaper further adds that tier-2 cities Chandigarh, Lucknow, Gandhinagar, Vadodara, Shillong, Jamshedpur, and Bidadi experienced substantial growth in event participation, propelled by multi-city tours and regional festivals that expanded audience bases and boosted local economic activities.
These developments reflect a dynamic shift towards a fan-centric, experience-driven economy, transcending traditional ticketing models.
Indian consumers are increasingly travelling inter-state, and investing substantially in hospitality, merchandise, and F&B, creating robust micro-economies around live entertainment.
The whitepaper stated that strategic investments and platform consolidations have accelerated growth.
Zomato's acquisition of Insider and the launch of lifestyle-oriented platforms such as District and Warner's investments in Skillbox exemplify a growing convergence of entertainment, technology, and consumer engagement.
International labels and domestic stakeholders alike are actively investing, highlighting global confidence in India's live events sector, as per the whitepaper.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Observer
a day ago
- Observer
Filmmakers try to cash in on India-Pakistan battle
Mumbai - Indian filmmakers are locking up the rights to movie titles that can profit from the patriotism fanned by a four-day conflict with Pakistan, which killed more than 70 people. The nuclear-armed rivals exchanged artillery, drone, and air strikes in May, after India blamed Pakistan for an armed attack on tourists in Indian-administered Kashmir. The fighting came to an end when US President Donald Trump announced a surprise ceasefire. Now, some Bollywood filmmakers see an opportunity to cash in on the battle. India tagged its military action against Pakistan 'Operation Sindoor', the Hindi word for vermilion, which married Hindu women wear on their foreheads. The name was seen as a symbol of Delhi's determination to avenge those widowed in the April 22 attack in Kashmir's Pahalgam, which sparked the hostilities. Film studios have registered a slew of titles evoking the operation, including: 'Mission Sindoor', 'Sindoor: The Revenge', 'The Pahalgam Terror', and 'Sindoor Operation'. "It's a story which needs to be told," said director Vivek Agnihotri. "If it were Hollywood, they would have made 10 films on this subject. People want to know what happened behind the scenes," he told AFP. Agnihotri struck box office success with his 2022 release, "The Kashmir Files", based on the mass flight of Hindus from Kashmir in the 1990s. - Coloured narratives - The ruling Bharatiya Janata Party gave that film a glowing endorsement, despite accusations that it aimed to stir up hatred against India's minority. Since Hindu nationalist Prime Minister Narendra Modi took office in 2014, some critics say Bollywood is increasingly promoting his government's ideology. Raja Sen, a film critic and screenwriter, said filmmakers felt emboldened by an amenable government. "We tried to wage a war, and then we quietened down when Trump asked us to. So what is the valour here?" Sen told AFP of the Pakistan clashes. Anil Sharma, known for directing rabble-rousing movies, criticised the apparent rush to make films related to the Pahalgam attack. "This is herd mentality... these are seasonal filmmakers, they have their constraints," he said. "I don't wait for an incident to happen and then make a film based on that. A subject should evoke feelings and only then cinema happens," said Sharma. Sharma's historical action flick "Gadar: Ek Prem Katha" (2001) and its sequel "Gadar 2" (2023), both featuring Sunny Deol in lead roles, were big hits. In Bollywood, filmmakers often seek to time releases for national holidays like Independence Day, which are associated with heightened patriotic fervour. "Fighter", featuring big stars Hrithik Roshan and Deepika Padukone, was released on the eve of India's Republic Day on January 25 last year. - Anti-Muslim bias - Though not a factual retelling, it drew heavily from India's 2019 airstrike on Pakistan's Balakot. The film received mixed-to-positive reviews but raked in $28 million in India, making it the fourth highest-grossing Hindi film of that year. This year, "Chhaava", a drama based on the life of Sambhaji Maharaj, a ruler of the Maratha Empire, became the highest-grossing film so far this year. It also generated significant criticism for fuelling anti-Muslim bias. "This is at a time when cinema is aggressively painting Muslim kings and leaders in violent light," said Sen. "This is where those who are telling the stories need to be responsible about which stories they choose to tell." Sen said filmmakers were reluctant to choose topics that are "against the establishment". "If the public is flooded with dozens of films that are all trying to serve an agenda, without the other side allowed to make itself heard, then that propaganda and misinformation enters the public psyche," he said. Acclaimed director Rakeysh Omprakash Mehra said true patriotism is promoting peace and harmony through the medium of cinema. Mehra's socio-political drama "Rang De Basanti" (2006) won the National Film Award for Best Popular Film and was chosen as India's official entry for the Golden Globe Awards and the Academy Awards in the Best Foreign Language Film category. "How we can arrive at peace and build a better society? How can we learn to love our neighbours?" he asked. "For me that is patriotism."
Observer
2 days ago
- Observer
India reels from the shock of Trump's onslaught
NEW DELHI — President Donald Trump's new list of tariffs on half the world's countries sent the United States' trading partners scrambling to understand how their businesses will be affected. India got the bad news a day earlier — its goods face a tariff of 25% or more — but the extra time was hardly enough to adjust to the fresh chaos. Indian negotiators had not expected to conclude a meaningful deal in time to meet Trump's revised deadline of Aug. 1. But they did expect to be treated as well as their neighbors, and to keep haggling with U.S. officials until October or November, when Trump was invited to visit India as part of the Quad defense group, which brings together four big democracies — India, the United States, Japan and Australia — with a shared interest in standing up to China. Instead, they were fed a heap of insults and injuries. Along with the 25% rate, one of the highest in Asia and only a point lower than what was threatened on 'Liberation Day' in April, India was informed that its existing trade barriers are 'strenuous and obnoxious'; it will be charged an untold penalty for buying Russian oil; it is a 'dead economy.' It's archrival Pakistan was praised and promised an oil exploration deal. Hurt feelings aside, the results are confusing. Two of the biggest categories of exports to the United States from India are personal electronics, worth about $14 billion a year, and pharmaceuticals, worth $10 billion. Rajesh Sharma, executive director of India Cellular and Electronics Association, said smartphones were exempted from these tariffs; so did executives at pharmaceutical companies. But on Friday, after reading the executive order, the Global Trade Research Initiative in New Delhi concluded the opposite. India's stock markets dipped on the news for two days running. Indian and international banks wrote notices warning that the country's generally hard-charging economic growth is likely to slow measurably as a result of the tariffs. Then there are the unknown tariffs. On July 6, Trump wrote that countries aligned with the BRICS group, of which India is a founding member, would incur an additional 10% penalty. Then on July 14, he said that, if Russia didn't make peace with Ukraine within 50 days, he would punish its trading partners with 'secondary tariffs' of 100%. That figure is making Indians worry anew. Trump added 'plus a penalty' to the 25% rate imposed on India, for buying Russian oil and weapons. Shashi Tharoor, a prominent member of the opposition, spoke to an Indian news agency about the possible impact. 'There's even talk of a 100% penalty,' he said, 'which will destroy our trade with America.' There is evidence that Indian buyers of Russian oil were already pulling back before the executive order. 'Indian refiners have reduced Russian crude purchases this week,' said Sumit Ritolia, an analyst at Kpler, which tracks shipping and commodities. They were already 'looking to further diversify, amid rising concerns over potential U.S. sanctions,' having spent years taking advantage of discounted Russian oil to reduce their imports from the Persian Gulf. Reducing the United States' trade deficit is one of the Trump administration's goals, so persuading India to buy more American oil and gas would make sense. Last year, India exported $45.7 billion more goods to the United States than it imported. It spent about three times as much importing oil. If a third of that were redirected to American sources, their bilateral trade would be evened out. Trump's angry barrage of social media has complicated further negotiations. The breakdown of trust between Narendra Modi, India's prime minister, whom Trump called his 'true friend,' the U.S. president is likely to make it harder to complete any deal, analysts say. Indian news outlets have reported that Trump wanted to iron out some outstanding issues, after four rounds of direct talks between the two sides, in a phone call with Modi. The Indian government was anxious to avoid any of his last-minute surprises. The U.S. commerce secretary accused India of 'slow-rolling' its trade negotiations. Indian officials and analysts say the friction is caused by a fundamental difference of approach. Trump has a penchant for quick, top-down dealmaking. India's bureaucracy moves at a methodical pace, especially when it comes to opening up the agriculture market, which is politically sensitive. India's recently concluded trade deal with Britain took three years of talks, under two British prime ministers. On Friday, India's Foreign Ministry released a statement that put on a brave face. 'India and the United States share a Comprehensive Global Strategic Partnership,' established in 2013 between President Barack Obama and then-Prime Minister Manmohan Singh, 'anchored in shared interests, democratic values and robust people-to-people ties.' The ministry stuck to principles, revealing no plan for breaking through Trump's hard line. 'This partnership has weathered several transitions and challenges,' the statement said. 'We remain focused on the substantive agenda that our two countries have committed to and are confident that the relationship will continue to move forward.' This article originally appeared in
Times of Oman
3 days ago
- Times of Oman
Pharma businesses ready with contingency plans faced with US tariffs: Association of Healthcare Providers (India)
New Delhi: Indian pharmaceutical manufacturers are preparing a two-pronged strategy to offset the impact of the soon-to-be-effective 25 per cent US tariff on Indian goods, which includes drug exports, with industry experts anticipating that the move could significantly raise medicine costs in the American market. Girdhar Gyani, Director General of the Association of Healthcare Providers (India), has voiced concern over the financial burden the proposed US tariff would impose on both Indian exporters and American consumers. India currently supplies around 47 per cent of the US pharmaceutical market, largely in the form of affordable generics. "If the United States enforces this 25 per cent tariff, the cost of drug delivery in the US will inevitably rise. Our estimates show that American drug prices could increase by 20 to 25 per cent annually -- a burden of nearly USD 6 to USD 7 billion. It's unclear whether the US healthcare system can absorb such an impact," Gyani said. According to its website, the Association of Healthcare Providers (India) , a non-profit organisation, represents the majority of healthcare providers in India. Despite the initial blow to Indian manufacturers, Gyani stated that industry players are already preparing contingency plans. One such measure is ramping up production in US-based and Mexico-based facilities owned by Indian firms, which, according to Gyani, would bypass the tariff restrictions. "The second approach involves a shift in focus from basic generics to value-added combination drugs. These combination drugs, which offer the convenience of two medicines in one, can be priced higher despite having similar production costs," he noted. The goal is to increase the volume and price range of such drugs, thereby maintaining competitiveness even under the new tariff regime. Gyani also suggested that continued diplomatic engagement between New Delhi and Washington could help mitigate the situation. "Negotiations between the two governments are likely to continue, and we may eventually see a reduction or reconsideration of the tariff policy," he said. The executive order signed by President Donald Trump on Thursday has imposed a flat 25 per cent tariff on all goods from India, with no product-level exemptions. The pharmaceutical sector has been a key pillar of India-US trade relations.
